Bioxytran ( (BIXT) ) has released a notification of late filing.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Bioxytran, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The primary reason for the delay is that the company’s independent registered public accounting firm requires additional time to complete the audit of the financial statements. Bioxytran anticipates filing the report within the fifteen-day grace period allowed under Rule 12b-25 of the Securities Exchange Act of 1934. The company does not expect any significant changes in its financial results from the previous fiscal year. Bioxytran is committed to maintaining compliance and transparency, as evidenced by the notification signed by CEO David Platt.
More about Bioxytran
YTD Price Performance: 79.01%
Average Trading Volume: 289,200
Technical Sentiment Signal: Hold
Current Market Cap: $12.78M
Find detailed analytics on BIXT stock on TipRanks’ Stock Analysis page.